

Luigi Formisano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1055626/publications.pdf>

Version: 2024-02-01

88
papers

3,221
citations

147726

31
h-index

168321

53
g-index

94
all docs

94
docs citations

94
times ranked

6252
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase Ib Study of Alpelisib (BYL719), a PI3K \pm -Specific Inhibitor, with Letrozole in ER+/HER2 $\hat{=}$ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 26-34.	3.2	268
2	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	5.8	252
3	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2488-2499.	0.4	178
4	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	1.3	160
5	Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 877-883.	3.4	125
6	Association of FGFR1 with ER $\hat{=}$ Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6138-6150.	3.2	94
7	Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. <i>Cancer Research</i> , 2016, 76, 440-452.	0.4	93
8	Genomic profiling of ER $\hat{=}$ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
9	Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 138-147.	3.2	87
10	The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. <i>British Journal of Cancer</i> , 2014, 110, 2887-2895.	2.9	80
11	Sp3/REST/HDAC1/HDAC2 Complex Represses and Sp1/HIF-1/p300 Complex Activates ncx1 Gene Transcription, in Brain Ischemia and in Ischemic Brain Preconditioning, by Epigenetic Mechanism. <i>Journal of Neuroscience</i> , 2015, 35, 7332-7348.	1.7	78
12	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1425-1435.	2.9	76
13	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 277-289.	3.2	74
14	MicroRNA-103-1 Selectively Downregulates Brain NCX1 and Its Inhibition by Anti-miRNA Ameliorates Stroke Damage and Neurological Deficits. <i>Molecular Therapy</i> , 2014, 22, 1829-1838.	3.7	63
15	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
16	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014, 16, R45.	2.2	56
17	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <i>Scientific Reports</i> , 2017, 7, 9388.	1.6	56
18	The Two Isoforms of the Na $\hat{=}$ /Ca $\hat{=}$ Exchanger, NCX1 and NCX3, Constitute Novel Additional Targets for the Prosurvival Action of Akt/Protein Kinase B Pathway. <i>Molecular Pharmacology</i> , 2008, 73, 727-737.	1.0	55

#	ARTICLE	IF	CITATIONS
19	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Oncolmmunology</i> , 2018, 7, e1438106.	2.1	54
20	<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6443-6451.	3.2	54
21	Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities. <i>Cancers</i> , 2019, 11, 1419.	1.7	54
22	Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. <i>British Journal of Cancer</i> , 2014, 111, 1168-1179.	2.9	49
23	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1959-1976.	2.5	44
24	Aspartate treatment attenuates myelin damage and stimulates myelin repair. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	44
25	c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?. <i>Cancers</i> , 2020, 12, 1489.	1.7	43
26	Resveratrol via sirtuin-1 downregulates RE1-silencing transcription factor (REST) expression preventing PCB-95-induced neuronal cell death. <i>Toxicology and Applied Pharmacology</i> , 2015, 288, 387-398.	1.3	38
27	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015, 6, 26090-26103.	0.8	37
28	p38/Sp1/Sp4/HDAC4/BDNF Axis Is a Novel Molecular Pathway of the Neurotoxic Effect of the Methylmercury. <i>Frontiers in Neuroscience</i> , 2017, 11, 8.	1.4	34
29	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	7.7	33
30	Histone deacetylase 4 promotes ubiquitin-dependent proteasomal degradation of Sp3 in SH-SY5Y cells treated with di(2-ethylhexyl)phthalate (DEHP), determining neuronal death. <i>Toxicology and Applied Pharmacology</i> , 2014, 280, 190-198.	1.3	32
31	Methylmercury upregulates RE-1 silencing transcription factor (REST) in SH-SY5Y cells and mouse cerebellum. <i>NeuroToxicology</i> , 2016, 52, 89-97.	1.4	32
32	The neurotoxicant PCB-95 by increasing the neuronal transcriptional repressor REST down-regulates caspase-8 and increases Ripk1, Ripk3 and MLKL expression determining necroptotic neuronal death. <i>Biochemical Pharmacology</i> , 2017, 142, 229-241.	2.0	31
33	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	2.3	31
34	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4379-4396.	3.2	30
35	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	29
36	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019, 11, 981.	1.7	29

#	ARTICLE	IF	CITATIONS
37	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. <i>Clinical Cancer Research</i> , 2019, 25, 771-783.	3.2	29
38	Mechanisms of resistance to mTOR inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 147, 102886.	2.0	27
39	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 2517-2529.	3.2	26
40	MS-275 Inhibits Aroclor 1254-Induced SH-SY5Y Neuronal Cell Toxicity by Preventing the Formation of the HDAC3/REST Complex on the Synapsin-1 Promoter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 352, 236-243.	1.3	25
41	Resveratrol treatment reduces the vulnerability of SH-SY5Y cells and cortical neurons overexpressing SOD1-G93A to Thimerosal toxicity through SIRT1/DREAM/PDYN pathway. <i>NeuroToxicology</i> , 2019, 71, 6-15.	1.4	25
42	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	5.8	25
43	MC1568 Inhibits Thimerosal-Induced Apoptotic Cell Death by Preventing HDAC4 Up-Regulation in Neuronal Cells and in Rat Prefrontal Cortex. <i>Toxicological Sciences</i> , 2016, 154, 227-240.	1.4	24
44	Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models. <i>Oncotarget</i> , 2015, 6, 10563-10576.	0.8	24
45	Anti-miR-223-5p Ameliorates Ischemic Damage and Improves Neurological Function by Preventing NCKX2 Downregulation after Ischemia in Rats. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 1063-1071.	2.3	23
46	The Repressor Element 1-Silencing Transcription Factor Is a Novel Molecular Target for the Neurotoxic Effect of the Polychlorinated Biphenyl Mixture Aroclor 1254 in Neuroblastoma SH-SY5Y Cells. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 338, 997-1003.	1.3	22
47	Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody. <i>Proteomics</i> , 2013, 13, 866-877.	1.3	21
48	Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models. <i>Clinical Cancer Research</i> , 2015, 21, 4153-4164.	3.2	21
49	Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer. <i>British Journal of Cancer</i> , 2013, 109, 686-693.	2.9	20
50	The miR206-JunD Circuit Mediates the Neurotoxic Effect of Methylmercury in Cortical Neurons. <i>Toxicological Sciences</i> , 2018, 163, 569-578.	1.4	20
51	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259.	1.7	18
52	Extracellular signal-related kinase 2/specificity protein 1/specificity protein 3/repressor element-1 silencing transcription factor pathway is involved in Aroclor 1254-induced toxicity in SH-SY5Y neuronal cells. <i>Journal of Neuroscience Research</i> , 2015, 93, 167-177.	1.3	17
53	Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. <i>British Journal of Cancer</i> , 2013, 108, 1616-1623.	2.9	15
54	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Transcriptional and epigenetic regulation of ncx1 and ncx3 in the brain. <i>Cell Calcium</i> , 2020, 87, 102194.	1.1	14
56	Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies. <i>World Journal of Clinical Oncology</i> , 2012, 3, 111.	0.9	14
57	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188595.	3.3	13
58	HDAC4 and HDAC5 form a complex with DREAM that epigenetically down-regulates NCX3 gene and its pharmacological inhibition reduces neuronal stroke damage. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 2081-2097.	2.4	12
59	Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1166.	1.8	10
60	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885.	2.0	9
61	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	2.0	9
62	Quis Custodiet Ipsos Custodes (Who Controls the Controllers)? Two Decades of Studies on HDAC9. <i>Life</i> , 2021, 11, 90.	1.1	9
63	From Biology to Therapy: Improvements of Therapeutic Options in Lung Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 18, 1235-1240.	0.9	9
64	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103649.	2.0	9
65	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	8
66	Prolonged NCX activation prevents SOD1 accumulation, reduces neuroinflammation, ameliorates motor behavior and prolongs survival in a ALS mouse model. <i>Neurobiology of Disease</i> , 2021, 159, 105480.	2.1	8
67	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094797.	1.4	7
68	Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis. <i>JMIR Cancer</i> , 2022, 8, e35930.	0.9	7
69	Tumor-to-tumor metastasis. <i>Anti-Cancer Drugs</i> , 2013, 24, 759-764.	0.7	5
70	Paraneoplastic Sensitive Neuropathy Associated with Anti-Hu Antibodies in a Neuroendocrine Tumor of Duodenum: A Case Report. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 1281-1285.	1.0	4
71	GATA3 (GATA-Binding Protein 3)/KMT2A (Lysine-Methyltransferase-2A) Complex by Increasing H3K4-3me (Trimethylated Lysine-4 of Histone-3) Upregulates NCX3 (Na ⁺ -Ca ²⁺ Exchanger) Tj ETQq1.1 0.784314 rgB / 3680-3691.	1.0	4
72	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. <i>Oncolmmunology</i> , 2013, 2, e25123.	2.1	3

#	ARTICLE	IF	CITATIONS
73	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. <i>Cancers</i> , 2021, 13, 4939.	1.7	3
74	Abstract GS6-06: A neoadjuvant trial with letrozole identifies PRR11 in the 17q23 amplicon as a mechanism of resistance to endocrine therapy in ER-positive breast cancer. , 2020, , .		2
75	Identification and characterization of the promoter and transcription factors regulating the expression of cerebral sodium/calcium exchanger 2 (NCX2) gene. <i>Cell Calcium</i> , 2022, 102, 102542.	1.1	2
76	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13509-e13509.	0.8	1
77	The Transcriptional Complex Sp1/KMT2A by Up-Regulating Restrictive Element 1 Silencing Transcription Factor Accelerates Methylmercury-Induced Cell Death in Motor Neuron-Like NSC34 Cells Overexpressing SOD1-G93A. <i>Frontiers in Neuroscience</i> , 2021, 15, 771580.	1.4	1
78	Decision making in clinical stage I (CSI) testicular cancer (TC).. <i>Journal of Clinical Oncology</i> , 2012, 30, e15034-e15034.	0.8	0
79	Abstract 950: Src tyrosine kinase contributes to lapatinib resistance in human breast cancer models.. , 2013, , .		0
80	Abstract 4508: Genomic profiling of ER+ breast cancers treated with prolonged neoadjuvant letrozole reveal a high frequency of NOTCH2 mutations in clinically resistant tumors. , 2016, , .		0
81	Abstract 1828: Hyperactivation of mTORC1 drives acquired resistance to the pan HER tyrosine kinase inhibitor neratinib in HER2 mutant cancers. , 2018, , .		0
82	Abstract 4008: Activating HER2 (ERBB2) mutations lead to endocrine therapy resistance through S6K activation. , 2018, , .		0
83	Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
84	Abstract P3-06-08: Pak1 as a novel mediator of resistance to endocrine therapy and CDK4/6 inhibitors in ER+/PAK-1 amplified breast cancer. , 2020, , .		0
85	Abstract PD7-04: Fibroblast growth factor receptor 1 associates with promoters genome-wide and regulates gene transcription in ER+/FGFR1-amplified breast cancer: Implications for endocrine resistance. , 2020, , .		0
86	Abstract P5-04-17: Hedgehog pathway is involved in cancer immune surveillance through PDL1 modulation. , 2020, , .		0
87	Abstract 4402: FGFR1 signaling modulates estrogen-independent ER transcriptional activity in ER+/FGFR1-amplified breast cancer cells. , 2019, , .		0
88	FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. <i>Future Oncology</i> , 0, , .	1.1	0